Stockscreener 앱 받기
4.75
2.37%
0.11
시간 외 거래:
4.74
-0.010
-0.21%
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Myriad Genetics (MYGN) Q4 earnings and revenues surpass estimates - MSN
Myriad Genetics receives FDA approval for ovarian cancer test By Investing.com - Investing.com South Africa
FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova - GuruFocus
Myriad Genetics receives FDA approval for ovarian cancer test - Investing.com
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - The Manila Times
FDA approves genetic test to match ovarian cancer patients to Zejula - Stock Titan
Portfolio Update: Can Myriad Genetics Inc maintain its current growth rate2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn
Myriad Genetics (MYGN) CTO has shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld - Stock Titan
Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax - Stock Titan
Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan
Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld - Stock Titan
Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan
Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax - Stock Titan
Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld - Stock Titan
Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion - AD HOC NEWS
Myriad Genetics, Inc. $MYGN Shares Sold by Anson Funds Management LP - MarketBeat
Market Review: Is now the right time to enter Myriad Genetics Inc2026 Selloffs & Accurate Intraday Trading Signals - baoquankhu1.vn
3 Reasons to Sell MYGN and 1 Stock to Buy Instead - Yahoo Finance
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care By Investing.com - Investing.com Canada
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - Finviz
Insider Buying: Samraat Raha Acquires 40,000 Shares of Myriad Ge - GuruFocus
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock - MarketBeat
Raha, Myriad Genetics CEO, buys $199k in shares - Investing.com Nigeria
Trading Systems Reacting to (MYGN) Volatility - Stock Traders Daily
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript - MSN
Myriad Genetics Q4 2025 earnings preview - MSN
Trading Recap: Whats next for Myriad Genetics Inc stockBreakout Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Take Profit: What hedge funds are buying Myriad Genetics IncMarket Sentiment Review & Weekly High Momentum Picks - baoquankhu1.vn
Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics, Inc. (MYGN) Competitors - Meyka
Myriad Genetics (NASDAQ: MYGN) files $200M shelf for equity and debt sales - Stock Titan
Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026News and Statistics - IndexBox
MYGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz
Myriad Commercially Launches Precise MRD with Select Community Oncologists - Bitget
Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan
New breast cancer test detects residual disease beyond standard scans - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research - MarketBeat
MYGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares - MarketBeat
Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock - MarketBeat
S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock - MarketBeat
Myriad Genetics Insider Bought Shares Worth $494,722, According to a Recent SEC Filing - marketscreener.com
Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 60% Upside Potential Amidst Financial Challenges - DirectorsTalk Interviews
How Myriad Genetics Inc. (MYGN) Affects Rotational Strategy Timing - Stock Traders Daily
Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN) - The Globe and Mail
GXD-Bio Appeals Genetic Tester IP Loss Against Myriad - Law360
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Inc files for mixed shelf of up to $200 millionSEC filing - marketscreener.com
Myriad Genetics Inc Files For Mixed Shelf Of Up To $200 MillionSEC Filing - TradingView
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead By Investing.com - Investing.com South Africa
Cancer, prenatal and mental health tests anchor Myriad (MYGN) 2025 plan - Stock Titan
MYGN: UBS Maintains Neutral Rating, Lowers Price Target to $6.00 - GuruFocus
MYGN: Wells Fargo Lowers Price Target for Myriad Genetics | MYGN Stock News - GuruFocus
0.55%
2.50%
자본화:
|
볼륨(24시간):